Can Evecxia Therapeutics turn EVX-101 into the first serotonin synthesis amplification therapy?
EVX-101 revives serotonin synthesis as an SSRI add-on strategy. Can Evecxia prove old biology still has new clinical value?
Can J&J’s lumateperone raise the bar for MDD remission? New CAPLYTA data fuels fresh hope
Johnson & Johnson (J&J) has presented new pooled data from Phase 3 clinical trials showing that CAPLYTA (lumateperone), used as an adjunctive therapy with antidepressants, significantly improved remission rates in adults with major depressive disorder compared to placebo. The results, highlighted at the 64th Annual Meeting of the American College of Neuropsychopharmacology, indicate nearly double […]